77 related articles for article (PubMed ID: 498090)
1. Specific inhibitors directed at the individual components of ribonucleotide reductase as an approach to combination chemotherapy.
Cory JG; Fleischer AE
Cancer Res; 1979 Nov; 39(11):4600-4. PubMed ID: 498090
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ribonucleotide reductase activity and nucleic acid synthesis in tumor cells by the dialdehyde derivatives of inosine (NSC 118994) and inosinic acid.
Cory JG; Mansell MM; Whitford TW
Cancer Res; 1976 Sep; 36(9 pt.1):3166-70. PubMed ID: 987850
[TBL] [Abstract][Full Text] [Related]
3. Studies on mammalian ribonucleotide reductase inhibition by pyridoxal phosphate and the dialdehyde derivatives of adenosine, adenosine 5'-monophosphate, and adenosine 5'-triphosphate.
Cory JG; Mansell MM
Cancer Res; 1975 Feb; 35(2):390-6. PubMed ID: 1109803
[TBL] [Abstract][Full Text] [Related]
4. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory AH; Sato A; Thompson DP; Cory JG
Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of combinations of drugs that inhibit Ehrlich tumor cell ribonucleotide reductase.
Sato A; Cory JG
Cancer Res; 1981 May; 41(5):1637-41. PubMed ID: 6783298
[TBL] [Abstract][Full Text] [Related]
6. Liver microsomal inactivation of 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone as an inhibitor of ribonucleotide reductase.
Williams MT; Simonet L; Cory AH; Cory JG
Cancer Res; 1988 Nov; 48(22):6375-8. PubMed ID: 3052801
[TBL] [Abstract][Full Text] [Related]
7. Reconstitution of the ribonucleotide reductase enzyme from Ehrlich tumor cells.
Cory JG; Fleischer AE; Munro JB
J Biol Chem; 1978 May; 253(9):2898-901. PubMed ID: 565357
[TBL] [Abstract][Full Text] [Related]
8. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
Carter GL; Cory JG
Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
[TBL] [Abstract][Full Text] [Related]
9. Mode of inhibition of tumor cell ribonucleotide reductase by 2,3-dihydro-1H-pyrazolo[2,3-a]imidazole (NSC 51143).
Cory JG; Fleischer AE
Cancer Res; 1980 Nov; 40(11):3891-4. PubMed ID: 6781737
[TBL] [Abstract][Full Text] [Related]
10. Herpes simplex virus ribonucleotide reductase induced in infected BHK-21/C13 cells: biochemical evidence for the existence of two non-identical subunits, H1 and H2.
Cohen EA; Charron J; Perret J; Langelier Y
J Gen Virol; 1985 Apr; 66 ( Pt 4)():733-45. PubMed ID: 2984316
[TBL] [Abstract][Full Text] [Related]
11. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
Cory JG; Carter GL
Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of inosine dialdehyde (NSC 118994) in the inhibition of proliferation of tumor cells in culture.
Plagemann PG; Graff JC; Behrens M
Cancer Res; 1977 Jul; 37(7 Pt 1):2188-95. PubMed ID: 193637
[TBL] [Abstract][Full Text] [Related]
13. Herpes simplex type 1 ribonucleotide reductase. Mechanism studies with inhibitors.
Spector T; Jones TE
J Biol Chem; 1985 Jul; 260(15):8694-7. PubMed ID: 2991215
[TBL] [Abstract][Full Text] [Related]
14. Dialdehyde derivative of 5'-deoxyinosine as a more potent analog of the dialdehyde derivative of inosine (NSC 118994).
Cory JG; Parker SH
Biochem Pharmacol; 1979 Mar; 28(6):867-71. PubMed ID: 454484
[No Abstract] [Full Text] [Related]
15. Substituted 2-acylpyridine-alpha-(N)-hetarylhydrazones as inhibitors of ribonucleotide reductase activity and L1210 cell growth.
Cory JG; Downes DL; Cory AH; Schaper KJ; Seydel JK
Anticancer Res; 1994; 14(3A):875-9. PubMed ID: 8074487
[TBL] [Abstract][Full Text] [Related]
16. Schedule-dependency assessments of ribonucleoside diphosphate reductase inhibitors when used in combination with platinum compounds plus cyclophosphamide in the treatment of advanced L1210 leukemia.
Gale GR; Atkins LM; Meischen SJ; Schwartz P
Cancer Treat Rep; 1979 Mar; 63(3):449-56. PubMed ID: 427825
[TBL] [Abstract][Full Text] [Related]
17. Effects of the ferrous chelate of 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone (MAIQ-1) on the kinetics of reduction of CDP by ribonucleotide reductase of the Novikoff tumor.
Preidecker PJ; Agrawal KC; Sartorelli AC; Moore EC
Mol Pharmacol; 1980 Nov; 18(3):507-12. PubMed ID: 7007866
[No Abstract] [Full Text] [Related]
18. Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory JG; Cory AH; Lorico A; Rappa G; Sartorelli AC
Anticancer Res; 1997; 17(5A):3185-93. PubMed ID: 9413147
[TBL] [Abstract][Full Text] [Related]
19. Noncoordinate changes in the components of ribonucleotide reductase in mammalian cells.
Cory JG; Fleischer AE
J Biol Chem; 1982 Feb; 257(3):1263-6. PubMed ID: 7035447
[TBL] [Abstract][Full Text] [Related]
20. Comparative cytotoxic and biochemical effects of ligands and metal complexes of alpha-N-heterocyclic carboxaldehyde thiosemicarbazones.
Saryan LA; Ankel E; Krishnamurti C; Petering DH; Elford H
J Med Chem; 1979 Oct; 22(10):1218-21. PubMed ID: 513069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
